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Abstract
In this study, cisplatin (CDDP)-loaded chitosan-coated solid lipid nanoparticles (SLN) was successfully formulated to
treat HeLa cervical carcinoma. The formulation nanoparticles were nanosized and exhibited a controlled release of
drug in physiological conditions. The blank nanoparticles exhibited an excellent biocompatibility profile indicating
its suitability for cancer targeting. The incorporation of CDDP in SLN remarkably increased the cancer cell death as
evident from the MTT assay. Importantly, CDDP-loaded chitosan-coated SLN (CChSLN) significantly (P < 0.05)
decreased the viability of cancer cells even at low concentration. The higher cytotoxicity potential of CChSLN was
attributed to the higher cellular uptake as well as the sustained drug release manner in comparison with CSLN.
Consistent with the cytotoxicity assay, CChSLN showed the lowest IC50 value of 0.6125 μg/ml while CSLN presented
1.156 μg/ml. CChSLN showed a significantly higher apoptosis in cancer cells compared to that of CSLN and CDDP,
which is attributed to the better internalization of nanocarriers and controlled release of anticancer drugs in the
intracellular environment. Our findings suggest that this new formulation could be a promising alternative for the
treatment of cervical cancers. These findings are encouraging us to continue our research, with a more extended
investigation of cellular response in real time and in animal models.
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Background
Human cervical cancer is one of the popular cancers in
women in reproductive age across the globe [1]. The
cervical cancer is caused by human papillomavirus
(HPV). International Agency for Research on Cancer has
stated the main factors responsible for the cervical
cancers including viral infection, inordinate sexual
behavior, depleted immune system, and smoking [2]. Re-
cent advances in cancer diagnosis and use of vaccine
have reduced the mortality rate of cervical cancer
patients; nevertheless, cancer-related death in China is
still high. Chemotherapy, surgery, and radiotherapy are
some of the treatment options in cervical cancers; however,
none is effective in controlling the cervical cancers [3].
Recently, two prophylactic HPV vaccines (Gardasil and
Cervarix) were marketed to tackle HPV-associated cervical
cancers; however, it was effective only in adult
patients and failed to show any therapeutic effect
against present cases. Especially, in the clinical
settings, chemotherapeutic drugs play an important
role in killing the cervical cancer cells [4, 5].
In this perspective, cis-dichlorodiammineplatinum(II)
(cis-[PtCl2(NH3)2], cisplatin (CDDP)) is a potent anti-
cancer agent for the treatment of various solid cancers
including cervical cancers [6]. CDDP kills the cancer
cells by crosslinking the DNA which in turn results in
the cellular apoptosis as the repair become unsuccessful.
The potent anticancer effect of CDDP is hindered by its se-
vere adverse effects such as nephrological and neurological
toxicities [7]. CDDP is normally associated with nephrotox-
icity that results in acute and chronic morbidity, while
neurotoxicity is cumulative-dose dependent. More than
everything, one of the biggest worries is the immediate
inactivation of CDDP in the systemic circulation that will
reduce its therapeutic potency and results in unwanted side
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effects [8, 9]. Therefore, efforts have to be made to protect
the pharmacological action of CDDP in systemic circulation
and prolong its systemic circulation. Furthermore, drug has
to be released in a sustained or controlled manner that will
improve its anticancer effect and reduce its associated side
effects.
The applications of principles of nanotechnology in
cancer treatment are expected to solve all the existing
problems. The drug loaded in a nanocarrier could effect-
ively protect the exposure of chemotherapeutic drug to
the extracellular environment [10]. Moreover, physio-
logical conditions of the diseased cancerous tissue offer
many benefits to the delivery system. The physiological
changes in the tumor tissue could be effectively used to
passively target the drug in the tumor. The poor lymphatic
drainage and increased vascular permeability in cancer
cells allows the drug-loaded nanoparticle to accumulate
passively in the tumor via enhanced permeation and re-
tention (EPR) effect. Additionally, nanoparticle will offer
multiple advantages such as increased stability, high load-
ing capacity, sustained release of drugs, and minimize the
drug-related side effects [11, 12].
In this regard, solid lipid nanoparticles (SLN) are re-
ported to be potential drug carriers. SLN provides some
of the unique benefits such as small particle size, high
surface area, spherical shape, and in vivo stability that
have generated huge enthusiasm in pharmaceutical and
biomedical enterprises [13–15]. Especially, SLN possess
the benefits of normal nanocarriers including polymeric
and lipid nanoparticles, simultaneously minimize its
drawbacks. The SLN carrier better protect the encapsu-
lated drugs in the biological circumstances and offer
better physiochemical features. However, one of the
main drawbacks of SLN is its inability to control the
drug release in the systemic conditions [16, 17]. There-
fore, effective strategies have to be made to prevent the
drug release and enhance the physicochemical properties
of SLN. Surface modification or assembly of biological
polymer coating could be employed to develop sustained
release characteristics SLN. Chitosan, non-toxic,
biodegradable, and biocompatible polysaccharide could
be an ideal choice to coat the SLN surface. The
chitosan-coated SLN is expected to act as a promising
vehicle for the delivery of CDDP in cervical cancers [18].
In the present study, a biocompatible chitosan was
employed for surface modification which will act like a
stealth layer (Fig. 1).
In this work, we primarily aimed to prepare chitosan-
coated SLN to effectively deliver CDDP in cervical
cancers. Towards this aim, drug-loaded nanoparticle was
characterized in terms of particle size, zeta potential,
morphology, and release characteristics. The anticancer
effect of free CDDP and CDDP-loaded SLN was investi-
gated in HeLa cervical cancer cells.
Methods
Materials
Compritol 888 ATO and monooleate of sorbitan ethoxy-
lated (Super refined Polysorbate 80TM; Tween 80TM)
were kindly provided by Gattefossé (Saint Priest, France).
Cisplatin and chitosan was purchased from Sigma-
Aldrich, China. All other chemicals were of analytical
grade and used as such.
Preparation of Cisplatin-Loaded Chitosan-Coated Solid
Lipid Nanoparticles
The SLN was formulated by hot homogenization
followed by emulsification-ultrasound method. Briefly,
100 mg of Compritol, 10 mg of lecithin, and 10 mg of
CDDP were melted above 60 °C and constitutes the oil
phase. The aqueous phase consists of Tween 80 (2%),
and the temperature was maintained similar to that of
oil phase. While maintaining the same temperature,
surfactant-containing phase was added slowly to the oil
phase under constant agitation. The mixture was imme-
diately homogenized using Ultra Turrax T-25
homogenizer for 5 min. The homogenized solution was
immediately subjected to high intensity probe sonication
(Vibracell VCX130; Sonics, USA) for 5 min. The emul-
sion was immediately cooled to 4 °C to allow the SLN
Fig. 1 Graphical presentation of the preparation of cisplatin-loaded chitosan-coated solid lipid nanoparticles
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formation. For chitosan coating, 0.1% chitosan solution
was prepared in 0.1% acetic acid. The SLN and chitosan
solution was mixed and stirred for 2 h at 100 rpm. The
chitosan-coated SLN was separated and lyophilized (if
necessary) and stored.
Dynamic Light Scattering Analysis
The size distribution was analyzed by dynamic light
scattering technique using BI-200SM, Brookhaven
Instruments Corp., Holtsville, NY, USA, equipped
with a 35-mM HeNe laser beam at a wavelength of
637 nm. The zeta potential of nanoparticle was ana-
lyzed using laser Doppler velocimeter (Zetasizer Nano
ZS90, Malvern, UK).
Drug Encapsulation Efficiency and Drug Loading
The CDDP-entrapped nanocarriers were centrifuged at
high speed (15,000 rpm), and the supernatant was col-
lected to evaluate the amount of unloaded drugs. HPLC
method was used to quantify the drug loading and en-
trapment efficiency. HPLC (Agilent LC 1100, Santa
Clara, CA, USA) was used. The column consists of
Inertsils ODS-3 column (150 4.6 μm, pore size 5 μm,
GL Science Inc., Tokyo, Japan) was used.
In Vitro Drug Release
Dialysis method was used to perform the release study.
Briefly, 1 ml of drug-loaded nanoparticles was packed in
a dialysis membrane (Spectra/Por 6, MWCO 3000,
Spectrum Laboratories, Inc., TX, USA) and both the
ends were sealed. The dialysis membrane was sealed and
kept in 20 ml of release buffer and in turn placed in a
shaker bath at 100 rpm. At specific time point, 1 ml of
release buffer was taken out and replenished with same
amount of new medium. The concentration of drug in
the release medium was quantified by HPLC method.
The mobile phase used was methanol/water/acetonitrile
(40:30:30 v/v/v) at 1 ml/min.
Cytotoxicity Assay
DMEM medium was used to grow HeLa cell which is
supplemented with 10% of FBS and 1% of antibiotic
mixture in an incubator at 37 °C. The cytotoxicity
assay was performed by MTT protocol. Briefly, 15,000
cells/well was seeded at each well of 96-well plate
and let it aside for 24 h. The old media was removed
and wells containing adherent cells were washed with
PBS. The cells were incubated with SLNs (0.01–
100 μg/mL) for 24 h. Also, free CDDP and CDDP-
loaded formulations were exposed to cancer cells and
incubated for 24 h. Following 24-h incubation, the
old media containing free SLN and drug-loaded for-
mulations were carefully aspirated and the cells were
washed twice with PBS. This process was carried out
in order to minimize the chance of carrier or drug
that is not internalized by the cells and avoid any
interference of the materials on the final absorbance.
The cells were then added with 10 μl of MTT (5 mg/
ml) and incubated for 4 h. Then MTT solution was
removed or aspirated carefully, and cells were added
with 150 μl of DMSO to solubilize the formazan
crystals. The well plates were then kept aside for
15 min, and absorbance was studied at 570 nm using
a POLAR star microplate reader (Omega, BMG
LabTech). The IC50 value was calculated from using
GraphPad prism software.
Apoptosis Assay
The apoptosis assay was performed by Annexin V/PI
staining. In brief, cells (2 × 105) were seeded in 12-
well plate and left aside for 24 h. The cells were
treated with respective formulations and left
untouched for 24 h. The cells were washed, isolated,
and treated with Annexin V and PI dye for 15 min in
dark conditions. The cells were then resuspended in
PBS and studied using flow cytometer (BD
Biosciences, USA).
Statistical Analysis
Analyses for the cytotoxicity studies were performed
using one-way ANOVA followed by Tukey’s test. P value
<0.05 was considered statistically significant for all
analyses.
Results and Discussion
Physicochemical Characterization of CChSLN
SLN was prepared by hot homogenization followed by
emulsification-ultrasound method. Among all lipids,
we have selected Compritol owing to its high loading
capacity and high bioavailability of encapsulated
drugs. CDDP-loaded SLN (CSLN) was prepared with
an average size of ~110 nm with an excellent disper-
sity index. The final particle size after chitosan coat-
ing becomes ~190 nm (Fig. 2). The particle size
increased due to the assembly of solid chitosan on
the outer surface of SLN. Furthermore, the CSLN
which we prepared possessed a negative ZP (approxi-
mately −26 mV) charge. The functional groups
present on the outer surface of NP led to the nega-
tive charge. The surface charge of CSLN reversed to
+22 mV after chitosan coating indicating the presence
of solid complimentary material on the nanocarrier
surface. It has been known that charge present on the
nanoparticle surface will decide its fate in vivo. The
positively charged nanoparticles will be beneficial as
the positively charged particle will interact favorably
with the cells containing negative charge [19]. It has
been reported that the small size of particle will be
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beneficial for the enhanced internalization of drugs
via endocytosis. It has been reported that SLN of
particle size between 80 and 300 nm could be inter-
nalized by various endocytosis pathways in cancer
cells. Moreover, no significant change in particle size of
CChSLN was observed when stored over the period of
5 weeks (data not shown). The results clearly reveal the ex-
cellent stability of SLN during cell culture investigations.
Furthermore, it would be nice if the size of SLNs prepared is
small as nanosized particles are more suitable for biomedical
applications.
In Vitro Drug Release Kinetics
The release of drug from CSLN and CChSLN was in-
vestigated. The phosphate-buffered saline (pH 7.4)
was used to simulate physiological conditions to carry
out release study (Fig. 3). As expected, release profile
of CSLN and CChSLN differed from each other. For
example, a typical biphasic release trend was ob-
served in CSLN where in approximately ~25% of
CDDP was released within first 10 h of release study
while remaining ~75% of drug released in 72 h. In
contrast, a well-controlled release of CDDP was
observed in CChSLN throughout the release study.
Approximately, ~50% of drug was released by the
end of the release study. A significant decrease in
the release of drug was observed after chitosan coat-
ing indicating the importance of presence of stealth
layer or protective layer. The decrease in the release
rate was attributed to the increase in the path length
of drug from the core of the nanoparticle to the
outer release media. It has been reported that the
Fig. 3 In vitro drug release profile of CSLN and CChSLN. The release study was performed in phosphate-buffered saline (PBS) at 37 °C for 72 h
Fig. 2 Particle size distribution of CSLN and CChSLN. The particle size of nanoparticles was measured by dynamic light scattering (DLS) technique
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solid status of the SLN at body temperature and
strong hydrophobic interaction of drug with lipid
nanoparticles is the main reason for the controlled
release of drug.
Cellular Uptake Analysis
The cellular uptake of CSLN and CChSLN was per-
formed by confocal laser scanning microscopy (CLSM)
(Fig. 4). As seen, CChSLN showed a remarkably higher
uptake in cancer cells compared to that of CLSN. The
marked cellular uptake of CChSLN in cancer cell was at-
tributed to the cationic surface charge of nanoparticles
that was internalized on the negatively surface charged
cellular membrane.
Biocompatibility of Blank Nanoparticles
The biocompatibility of SLN is one of the important cri-
teria for the successful application of nanocarrier in can-
cer targeting. As shown, both the blank nanoparticles
did not affect the growth of cancer cells (Fig. 5). Espe-
cially, cell viability remained more than >95% even when
treated highest concentration of blank SLN while the
cell viability remained more than >90% in case of
chitosan-coated SLN. A slight decrease in the cell
viability of chitosan-coated formulation was due to the
Fig. 5 Biocompatibility analysis of blank SLN and chitosan-coated SLN in HeLa cervical cancer cells
Fig. 4 In vitro cellular uptake of CSLN and CChSLN in HeLa cancer cells. Rhodamine B was used as a fluorescent probe
Wang et al. Nanoscale Research Letters  (2016) 11:524 Page 5 of 8
positive charge of chitosan polymer which may kill the
cancer cells sometimes. Overall, high cell viability war-
rants the safety profile and biocompatibility of SLN
formulations.
Cytotoxicity Assay of Free CDDP and CChSLN
For the successful treatment of cervical cancers, it is ut-
most important to improve the chemotherapeutic effi-
cacy of CDDP while reducing its side effects on the
normal cells. Towards this goal, we have applied the
nanotechnology principles to improve the biological and
pharmacological effects of CDDP at low concentrations
(Fig. 6). The cytotoxicity of CDDP, CSLN, and CChSLN
was investigated in HeLa cervical cancer cells using
MTT method. The results indicate that the viability of
cancer cells were typically dependent on the concentra-
tion of drug or drug-loaded formulations. The free
CDDP although reduced the cell viability of cancer cells,
it was not very effective. As expected, incorporation of
CDDP in SLN remarkably increased the cancer cell
death as evident from the MTT assay. Importantly,
CChSLN significantly decreased the viability of cancer
cells even at low concentration. The higher cytotoxicity
potential of CChSLN was due to the better internaliza-
tion in the cancer cells and controlled release of encap-
sulated component in comparison with CSLN. The
positively charged CChSLN is expected to internalize in
higher rate and increase the concentration gradient of
Fig. 7 IC50 value of CDDP, CSLN, and CChSLN in HeLa cervical cancer cells
Fig. 6 Cytotoxicity potential of CDDP, CSLN, and CChSLN in HeLa cervical cancer cells. The cytotoxicity of formulations was analyzed by MTT assay
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CDDP in the cancer cells. In addition, nanoparticles
greatly help minimize the multidrug resistance which is
responsible for the elimination of many anticancer drugs
by a unique p-glycoprotein.
The antitumor effect of different formulations was fur-
ther quantified by IC50 value, which is defined as the
amount of drug required to kill 50% of cells in the desig-
nated time interval (Fig. 7). Consistent with the cytotox-
icity assay, CChSLN showed the lowest IC50 value of
0.6125 μg/ml while CSLN presented 1.156 μg/ml. The
CDDP showed an IC50 value of 1.602 μg/ml which is
highest among all the formulations tested. The data
clearly show the advantage of the nanoparticle formula-
tion vs. free CDDP.
Microscopic Analysis
The cancer cells were treated with individual items
and incubated for 24 h. The morphology of cancer
cells was consistent with the cytotoxicity data. As
shown, CChSLN-treated cells were fewer and round
morphology indicating the higher cytotoxicity of the
formulations (Fig. 8). The untreated cells were
normal and spread over the six-well plate whereas
formulation treated group clearly showed the shrink-
age and apoptosis of cancer cells. Results clearly
reveal that chitosan-coated NP effectively kills the
cancer cells and could be beneficial for the cancer
treatment.
Apoptosis Analysis
The apoptosis analysis was carried out by Annexin V/PI
staining assay. As seen, free CDDP slightly induced an apop-
tosis of cervical cancer cells while CSLN exhibited a rela-
tively higher cellular apoptosis in this cancer cells (Fig. 9).
As expected, CChSLN showed a significantly higher apop-
tosis in cancer cells which is attributed to the better internal-
ization of nanocarriers and controlled release of anticancer
drugs in the intracellular environment. The CChSLN
showed nearly ~40% of cell apoptosis compared to that of
~28 and 12% for CSLN and CDDP, respectively.
Conclusions
In conclusion, CDDP-loaded chitosan-coated SLN was
successfully formulated to treat HeLa cervical carcin-
oma. The formulation nanoparticles were nanosized and
exhibited a controlled diffusion of drug in neutral condi-
tions. The blank nanoparticles exhibited an excellent
biocompatibility profile indicating its suitability for can-
cer targeting. The incorporation of CDDP in SLN re-
markably increased the cancer cell death as evident from
the MTT assay. Importantly, CChSLN significantly de-
creased the viability of cancer cells even at low concen-
tration. The higher cytotoxicity potential of CChSLN
might be due to that enhanced cellular internalization
and controlled release of encapsulated component in
comparison with CSLN. Consistent with the cytotoxicity
assay, CChSLN showed the lowest IC50 value of
Fig. 9 The apoptosis analysis of formulations in cancer cells. The apoptosis assay was carried out by Annexin V/PI staining and determined by
flow cytometer
Fig. 8 Morphological analysis of cancer cells after treatment with CDDP, CSLN, and CChSLN
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0.6125 μg/ml while CSLN presented 1.156 μg/ml.
CChSLN showed a significantly higher apoptosis in can-
cer cells compared to that of CSLN and CDDP, which is
attributed to the better internalization of nanocarriers
and controlled release of anticancer drugs in the intra-
cellular environment. Our results clearly reveal that
these unique formulations could be a better choice for
cervical cancer treatment. The investigative findings en-
courage us to carry out in-depth biological and in vivo
analysis of the present system.
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